Dose Optimization in General Practice: Strategies, Evidence, and Clinical Implications

Abstract

Dose optimization is a cornerstone of safe, effective, and patient-centered care in general practice. This review synthesizes current evidence, clinical guidelines, and emerging approaches to dose optimization, emphasizing its impact on therapeutic outcomes, adverse event reduction, and healthcare resource utilization. Mechanism-based rationale, risk stratification, and practical strategies for dose adjustment are discussed to equip general practitioners with actionable knowledge for individualized patient care.

Introduction

General practitioners (GPs) routinely encounter scenarios requiring precise medication dosing to maximize efficacy while minimizing harm. Dose optimization—tailoring drug regimens to individual patient characteristics—has become increasingly important due to aging populations, multimorbidity, polypharmacy, and evolving pharmaceutical innovations. This article reviews the epidemiology, pathophysiological considerations, risk factors, clinical features, diagnostic challenges, and management strategies central to dose optimization in primary care, guided by recent evidence and consensus recommendations.

Epidemiology / Disease Burden

Suboptimal dosing is a widespread issue in primary care, contributing to preventable adverse drug reactions (ADRs), therapeutic failures, and hospitalizations. Studies indicate that up to 15% of hospital admissions in older adults are medication-related, with dose mismanagement playing a significant role. The global increase in chronic disease prevalence and polypharmacy further amplifies the complexity of dosing decisions, highlighting dose optimization as a public health priority in general practice.

Pathophysiology

Dose requirements are influenced by pharmacokinetic and pharmacodynamic variability among individuals. Factors such as age-related changes in renal and hepatic function, genetic polymorphisms affecting drug metabolism (e.g., CYP450 enzymes), and comorbidities can alter drug absorption, distribution, metabolism, and excretion. Understanding these mechanisms is fundamental to predicting patient-specific responses and guiding rational dose adjustments.

Risk Factors

Key risk factors for inappropriate dosing include advanced age, renal or hepatic impairment, polypharmacy, drug-drug interactions, and low health literacy. Patients with chronic kidney disease, heart failure, or hepatic dysfunction often require dosage reductions or alternative therapies. Concomitant use of drugs metabolized by the same enzyme pathways increases the risk of toxicity or subtherapeutic effects, necessitating vigilant medication review and dose adjustment.

Clinical Features

Clinical manifestations of dosing issues range from lack of therapeutic response to overt toxicity. Symptoms may be nonspecific (e.g., confusion, falls, gastrointestinal disturbances) or organ-specific (e.g., nephrotoxicity, hepatotoxicity, arrhythmias). Detecting subtle signs of under- or overdosing is challenging but critical, especially in vulnerable populations such as the elderly or those with cognitive impairment.

Diagnosis

Diagnosing dosing errors relies on a combination of clinical assessment, medication reconciliation, and laboratory evaluation. Tools such as the Beers Criteria and STOPP/START criteria can help identify potentially inappropriate medications and dosing in older adults. Therapeutic drug monitoring (TDM) is essential for drugs with narrow therapeutic indices (e.g., warfarin, digoxin, lithium), supporting evidence-based dose adjustments based on serum concentrations and patient response.

Treatment & Management

Dose optimization strategies encompass initial dose selection, titration protocols, and ongoing monitoring. Individualized dosing takes into account patient age, weight, organ function, comorbidities, and concomitant medications. Shared decision-making, patient education, and regular follow-up are integral to successful dose management. For chronic therapies, periodic review is necessary to adjust dosages according to changing clinical status and emerging evidence.

Recent Advances / Emerging Therapies

Recent advances in dose optimization include the integration of pharmacogenomics, clinical decision support systems (CDSS), and artificial intelligence algorithms into primary care practice. Pharmacogenomic testing enables identification of genetic variants affecting drug metabolism, facilitating personalized dosing. CDSS, embedded in electronic health records, provide real-time alerts for dose adjustments based on renal function, age, and drug interactions. These innovations are reshaping the landscape of medication management in general practice.

Guideline Recommendations

International guidelines, such as those from the National Institute for Health and Care Excellence (NICE) and the American Geriatrics Society, emphasize regular medication review, use of validated dosing tools, and patient engagement in dose-related decisions. Recommendations call for dose adjustments in response to organ dysfunction, frailty, and pharmacogenetic findings. Adherence to evidence-based protocols is associated with improved safety and therapeutic outcomes.

Conclusion

Dose optimization is a dynamic, patient-centered process that underpins quality care in general practice. Mastery of pharmacological principles, risk stratification, and the use of modern tools and guidelines enable GPs to minimize adverse outcomes while ensuring maximal therapeutic benefit. Continuous education, multidisciplinary collaboration, and integration of emerging technologies are vital for advancing dose optimization and improving patient outcomes in the evolving landscape of primary care.